Elevated Lp(a) levels are associated with continuously increased risk of recurrent atherosclerotic cardiovascular disease (ASCVD) events, irrespective of sex and race/ethnicity, illustrating the unmet need for Lp(a) lowering therapy in diverse ASCVD populations.
Educational Partners and Supporters
AstraZeneca has provided a sponsorship grant towards this independent programme.
